Jan 1, 2013
By:
William Looney
2013 may be a number associated with the fate of the luckless, but our annual review of the business and policy environment for Big Pharma suggests otherwise—as we near the midway point in the "tween" decade, there is good fortune in store for those with the perspective that comes with the long view.
|
Dec 1, 2012
By:
William Looney
Europe's chief regulator charts a strategy from many moving parts. Dr Guido Rasi talks to Pharm Exec's William Looney.
|
|
Dec 1, 2012
By:
William Looney
The calendar says its wrap-up time, not just for gifts but for some of the trends that shaped the industry—for good or bad—in 2012.
|
Nov 1, 2012
By:
William Looney
Spain's leading business school, IESE, organized an expert conference on October 2-3 to address two simple questions. First, how can providers and payers work together to generate more value from existing resources? Second, what must be done to ensure the system continues to create value in the first place?
|
Oct 1, 2012
By:
William Looney
Developing a drug is still very much a game of chance: a round puzzle of soft edges, with pieces that rarely fit the hard rectangles of time and money. Solving the puzzle correctly—with a new product as the sum of its parts—depends on making that lengthy progression from basic science to registration as linear as possible.
|
|
Oct 1, 2012
By:
William Looney
Pharm Exec takes a look at how a mid tier player — Denmark's Lundbeck — is counting on the momentum of the big US market to vault it to global leadership position.
|
Sep 1, 2012
By:
William Looney
Autumn is a good time to present our annual post on how well the industry is doing in harvesting value for shareholders. Our diverse list of 24 companies, drawn from Big Pharma to the established biotechs, presents a similarly mixed picture on returns: smaller firms with a distinct customer base and tight oversight of costs are by and large proving more adept at delivering the strong growth that investors still expect from this business.
|
Aug 1, 2012
By:
William Looney
This month's feature by Ben Comer highlights what's behind the new Corporate Integrity Agreement (CIA) imposed on GSK by theHHS Office of Inspector-General to compensate for a long list of marketing and pricing malfeasances
|
Jul 30, 2012
By:
William Looney
Are there parallels between milk and medicine? To David Ford, a native New Zealander who now runs Sanofi's North America human resources operations, the answer is a qualified yes.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
